PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
Description
<jats:p>Proteolysis targeting chimeric (PROTAC) technology is an effective endogenous protein degradation tool developed in recent years that can ubiquitinate the target proteins through the ubiquitin-proteasome system (UPS) to achieve an effect on tumor growth. A number of literature studies on PROTAC technology have proved an insight into the feasibility of PROTAC technology to degrade target proteins. Additionally, the first oral PROTACs (ARV-110 and ARV-471) have shown encouraging results in clinical trials for prostate and breast cancer treatment, which inspires a greater enthusiasm for PROTAC research. Here we focus on the structures and mechanisms of PROTACs and describe several classes of effective PROTAC degraders based on E3 ligases.</jats:p>
Journal
-
- Frontiers in Pharmacology
-
Frontiers in Pharmacology 12 692574-, 2021-05-07
Frontiers Media SA
- Tweet
Details 詳細情報について
-
- CRID
- 1360857595667403648
-
- ISSN
- 16639812
-
- Data Source
-
- Crossref